Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taysha Gene TherapiesTSHA -2.71%33 3-Year EBITDA Growth Rate is 54.90% as of Jun. 2026, which is at its 10-year median of 54.90. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Taysha Gene Therapies ranks better than 88.55% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 44.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Taysha Gene Therapies was 57.50% per year. The lowest was 35.60% per year. And the median was 54.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Taysha Gene Therapies 3-Year EBITDA Growth Rate Related Terms
TSHA vs KARD, GHRS, VIR: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Taysha Gene Therapies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 54.90% mean?
Taysha Gene Therapies (TSHA) has a 3-Year EBITDA Growth Rate of 54.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Taysha Gene Therapies and its competitors. This is near median its historical median of 54.90. Over the past decade, Taysha Gene Therapies' 3-Year EBITDA Growth Rate has ranged from 35.60 to 57.50. According to the industry distribution chart, Taysha Gene Therapies ranks #129 out of 1127 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Taysha Gene Therapies' 3-Year EBITDA Growth Rate too high?
Taysha Gene Therapies' current 3-Year EBITDA Growth Rate of 54.90% is near median its 10-year median of 54.90. Over the past 10 years, this metric has ranged from a low of 35.60 to a high of 57.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Taysha Gene Therapies' value of 54.90% is 276% above this industry median. Based on the distribution chart, Taysha Gene Therapies ranks #129 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' 3-Year EBITDA Growth Rate compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #129 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Taysha Gene Therapies in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Taysha Gene Therapies' value of 54.90% is 276% above this benchmark. Historically, Taysha Gene Therapies' own 3-Year EBITDA Growth Rate has ranged from 35.60 to 57.50 over the past decade. While the company's 10-year median is 54.90 vs. the industry median of 14.60, Taysha Gene Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taysha Gene Therapies's current 3-Year EBITDA Growth Rate of 54.90% is 276% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Taysha Gene Therapies and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current 3-Year EBITDA Growth Rate is 54.90%, which is near median its own 10-year median of 54.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 54.90%, which is near median its 10-year median of 54.90 and 276% above the Biotechnology industry median of 14.60. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current 3-Year EBITDA Growth Rate is 54.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
3-Year EBITDA Growth Rate: 54.90% (near median its 10-year median of 54.90)
GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
Industry Position: 276% above the Biotechnology median (#129 of 1127)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
